| Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells RT Mitsuyasu, TC Merigan, A Carr, JA Zack, MA Winters, C Workman, ... Nature medicine 15 (3), 285-292, 2009 | 365 | 2009 |
| Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients T Volz, M Lutgehetmann, P Wachtler, A Jacob, A Quaas, JM Murray, ... Gastroenterology 133 (3), 843-852, 2007 | 251 | 2007 |
| Kinetics of acute hepatitis B virus infection in humans SA Whalley, JM Murray, D Brown, GJM Webster, VC Emery, GM Dusheiko, ... The Journal of experimental medicine 193 (7), 847-854, 2001 | 245 | 2001 |
| Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase JM Murray, S Emery, AD Kelleher, M Law, J Chen, DJ Hazuda, ... Aids 21 (17), 2315-2321, 2007 | 242 | 2007 |
| Dynamics of hepatitis B virus clearance in chimpanzees JM Murray, SF Wieland, RH Purcell, FV Chisari Proceedings of the National Academy of Sciences 102 (49), 17780-17785, 2005 | 196 | 2005 |
| Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination M Markowitz, X Jin, A Hurley, V Simon, B Ramratnam, M Louie, ... The Journal of infectious diseases 186 (5), 634-643, 2002 | 163 | 2002 |
| Optimal control for a cancer chemotheraphy problem with general growth and loss functions JM Murray Mathematical Biosciences 98 (2), 273-287, 1990 | 154 | 1990 |
| Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients JL Macpherson, MP Boyd, AJ Arndt, AV Todd, GC Fanning, JA Ely, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2005 | 151 | 2005 |
| Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty JM Murray, GR Kaufmann, PD Hodgkin, SR Lewin, AD Kelleher, ... Immunology and Cell Biology 81 (6), 487-495, 2003 | 148 | 2003 |
| The half-life of hepatitis B virions JM Murray, RH Purcell, SF Wieland Hepatology 44 (5), 1117-1121, 2006 | 137 | 2006 |
| CD4+ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4+ T … S Fernandez, S Tanaskovic, K Helbig, R Rajasuriar, M Kramski, ... The Journal of infectious diseases 204 (12), 1927-1935, 2011 | 125 | 2011 |
| Timing of the Components of the HIV Life Cycle in Productively Infected CD4+ T Cells in a Population of HIV-Infected Individuals JM Murray, AD Kelleher, DA Cooper Journal of virology 85 (20), 10798-10805, 2011 | 116 | 2011 |
| In vivo proliferation of hepadnavirus‐infected hepatocytes induces loss of covalently closed circular DNA in mice M Lutgehetmann, T Volz, A Köpke, T Broja, E Tigges, AW Lohse, E Fuchs, ... Hepatology 52 (1), 16-24, 2010 | 113 | 2010 |
| The prevalence of sexually transmitted infections in Papua New Guinea: a systematic review and meta-analysis A Vallely, A Page, S Dias, P Siba, T Lupiwa, G Law, J Millan, DP Wilson, ... PloS one 5 (12), e15586, 2010 | 107 | 2010 |
| Some optimal control problems in cancer chemotherapy with a toxicity limit JM Murray Mathematical Biosciences 100 (1), 49-67, 1990 | 107 | 1990 |
| HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy JM Murray, JJ Zaunders, KL McBride, Y Xu, M Bailey, K Suzuki, ... Journal of virology 88 (6), 3516-3526, 2014 | 102 | 2014 |
| The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users JM Murray, MG Law, Z Gao, JM Kaldor International Journal of Epidemiology 32 (5), 708-714, 2003 | 92 | 2003 |
| Optimal control for a stochastic model of cancer chemotherapy AJ Coldman, JM Murray Mathematical biosciences 168 (2), 187-200, 2000 | 91 | 2000 |
| The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology A Goyal, JM Murray PloS one 9 (10), e110143, 2014 | 88 | 2014 |
| Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir KK Koelsch, C Boesecke, K McBride, L Gelgor, P Fahey, V Natarajan, ... Aids 25 (17), 2069-2078, 2011 | 88 | 2011 |
